Literature DB >> 28079059

Co-Variation of Peripheral Levels of miR-1202 and Brain Activity and Connectivity During Antidepressant Treatment.

Juan Pablo Lopez1,2, Fabricio Pereira3, Stéphane Richard-Devantoy1,4, Marcelo Berlim1,4, Eduardo Chachamovich1,4, Laura M Fiori1,4, Paola Niola5, Gustavo Turecki1,4, Fabrice Jollant1,4,6.   

Abstract

MicroRNAs are short non-coding molecules that play a major role in regulating gene expression. Peripheral levels of miR-1202 have been shown to predict and mediate antidepressant response. However, it is not clear to what extent these peripheral measures reflect central neural changes in vivo. We approached this problem with the combined use of peripheral miR-1202 measures and neuroimaging. At baseline and after 8 weeks of desvenlafaxine (50-100 mg die), 20 patients were scanned with 3T magnetic resonance imaging, first at rest then during the Go/NoGo task, a classical test of response inhibition. Blood samples were collected at both time points. During resting state, lower baseline miR-1202 levels were predictive of increased connectivity from T0 to T8 between the posterior cingulate and the prefrontal, parietal, and occipital cortices. Changes in miR-1202 levels following desvenlafaxine treatment were negatively correlated with changes in activity in right precuneus within the default-mode network, and in connectivity between the posterior cingulate and the temporal and prefrontal cortices, and the precuneus. During the Go/NoGo task, baseline miR-1202 levels and changes in these levels were correlated with activity changes in different regions, including bilateral prefrontal, insular, cingulate, and temporal cortices, and left putamen and claustrum. Finally, secondary analyses in a subset of patients showed a trend for a significant correlation between miR-1202 levels and glutamate levels measured by spectroscopy. Changes in peripheral miR-1202 levels were therefore associated with changes in brain activity and connectivity in a network of brain regions associated with depression and antidepressant response. These effects may be mediated by the glutamatergic system.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28079059      PMCID: PMC5561353          DOI: 10.1038/npp.2017.9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  43 in total

1.  Neuropsychiatric symptoms in Alzheimer's disease are related to functional connectivity alterations in the salience network.

Authors:  Marcio L F Balthazar; Fabrício R S Pereira; Tátila M Lopes; Elvis L da Silva; Ana Carolina Coan; Brunno M Campos; Niall W Duncan; Florindo Stella; Georg Northoff; Benito P Damasceno; Fernando Cendes
Journal:  Hum Brain Mapp       Date:  2013-02-18       Impact factor: 5.038

Review 2.  Resting state networks in major depressive disorder.

Authors:  Arpan Dutta; Shane McKie; J F William Deakin
Journal:  Psychiatry Res       Date:  2014-10-13       Impact factor: 3.222

Review 3.  A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder.

Authors:  Gabriel S Dichter; Devin Gibbs; Moria J Smoski
Journal:  J Affect Disord       Date:  2014-09-26       Impact factor: 4.839

4.  Limbic-frontal circuitry in major depression: a path modeling metanalysis.

Authors:  D A Seminowicz; H S Mayberg; A R McIntosh; K Goldapple; S Kennedy; Z Segal; S Rafi-Tari
Journal:  Neuroimage       Date:  2004-05       Impact factor: 6.556

5.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.

Authors:  Hadi Valadi; Karin Ekström; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan O Lötvall
Journal:  Nat Cell Biol       Date:  2007-05-07       Impact factor: 28.824

6.  Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers.

Authors:  Rulun Zhou; Peixiong Yuan; Yun Wang; Joshua G Hunsberger; Abdel Elkahloun; Yanling Wei; Patricia Damschroder-Williams; Jing Du; Guang Chen; Husseini K Manji
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

Review 7.  Resting-state functional connectivity in major depressive disorder: A review.

Authors:  Peter C Mulders; Philip F van Eijndhoven; Aart H Schene; Christian F Beckmann; Indira Tendolkar
Journal:  Neurosci Biobehav Rev       Date:  2015-07-30       Impact factor: 8.989

Review 8.  FSL.

Authors:  Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

9.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

10.  miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment.

Authors:  Juan Pablo Lopez; Raymond Lim; Cristiana Cruceanu; Liam Crapper; Caroline Fasano; Benoit Labonte; Gilles Maussion; Jennie P Yang; Volodymyr Yerko; Erika Vigneault; Salah El Mestikawy; Naguib Mechawar; Paul Pavlidis; Gustavo Turecki
Journal:  Nat Med       Date:  2014-06-08       Impact factor: 53.440

View more
  14 in total

Review 1.  Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants.

Authors:  Raoul Belzeaux; Rixing Lin; Gustavo Turecki
Journal:  CNS Drugs       Date:  2017-04       Impact factor: 5.749

2.  Neural extracellular vesicle-derived miR-17 in blood as a potential biomarker of subthreshold depression.

Authors:  Yusuke Mizohata; Hiroyuki Toda; Minori Koga; Taku Saito; Masanori Fujita; Tetsuya Kobayashi; Shin Hatakeyama; Yuji Morimoto
Journal:  Hum Cell       Date:  2021-05-19       Impact factor: 4.174

3.  MiR-1202 Exerts Neuroprotective Effects on OGD/R Induced Inflammation in HM Cell by Negatively Regulating Rab1a Involved in TLR4/NF-κB Signaling Pathway.

Authors:  Shuhuan Song; Yan Pan; Hua Li; Honghua Zhen
Journal:  Neurochem Res       Date:  2020-03-02       Impact factor: 3.996

Review 4.  Progress in Epigenetics of Depression.

Authors:  Catherine J Peña; Eric J Nestler
Journal:  Prog Mol Biol Transl Sci       Date:  2018-04-10       Impact factor: 3.622

Review 5.  The important roles of microRNAs in depression: new research progress and future prospects.

Authors:  Chenggui Miao; Jun Chang
Journal:  J Mol Med (Berl)       Date:  2021-02-27       Impact factor: 4.599

6.  Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.

Authors:  Laura M Fiori; Juan Pablo Lopez; Stéphane Richard-Devantoy; Marcelo Berlim; Eduardo Chachamovich; Fabrice Jollant; Jane Foster; Susan Rotzinger; Sidney H Kennedy; Gustavo Turecki
Journal:  Int J Neuropsychopharmacol       Date:  2017-08-01       Impact factor: 5.176

Review 7.  miRNAs in depression vulnerability and resilience: novel targets for preventive strategies.

Authors:  Nicola Lopizzo; Valentina Zonca; Nadia Cattane; Carmine Maria Pariante; Annamaria Cattaneo
Journal:  J Neural Transm (Vienna)       Date:  2019-07-26       Impact factor: 3.575

8.  Faecal microRNAs as a non-invasive tool in the diagnosis of colonic adenomas and colorectal cancer: A meta-analysis.

Authors:  Tung On Yau; Ceen-Ming Tang; Elinor K Harriss; Benjamin Dickins; Christos Polytarchou
Journal:  Sci Rep       Date:  2019-07-01       Impact factor: 4.379

9.  A pilot study on differential expression of microRNAs in the ventromedial prefrontal cortex and serum of sows in activity restricted crates or activity free pens.

Authors:  Guoan Yin; Liwei Guan; Langchao Yu; Dapeng Huang
Journal:  Asian-Australas J Anim Sci       Date:  2019-04-15       Impact factor: 2.509

10.  MDMA Abuse in Relation to MicroRNA Variation in Human Brain Ventral Tegmental Area and Nucleus Accumbens.

Authors:  Goksun Demirel; Esra Guzel; Chad J Creighton; Yeter Erol Ozturk; Ceyhun Kucuk; Hızır Asliyuksek; Türkan Yurdun
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.